

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Heinrich et al.

Application No. 10/517,905

Filed: December 10, 2004

Confirmation No. 4619

FILED VIA EFS  
ON OCTOBER 9, 2006

For: ACTIVATING MUTATIONS OF  
PLATELET DERIVED GROWTH  
FACTOR RECEPTOR ALPHA (PDGFRA)  
AS DIAGNOSTIC MARKERS AND  
THERAPEUTIC TARGETS

Examiner: Zachary C. Howard

Art Unit: 1646

Attorney Reference No. 899-65892-02

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97(b)(3)

COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicants will provide copies of such patents or applications upon request.

Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

By



Sheree Lynn Rybak, Ph.D.  
Registration No. 47,913

cc: Docketing

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

<b>Attorney Docket Number</b>	899-65892-02
<b>Application Number</b>	10/517,905
<b>Filing Date</b>	December 10, 2004
<b>First Named Inventor</b>	Heinrich
<b>Art Unit</b>	1646
<b>Examiner Name</b>	Zachary C. Howard

## **U.S. PATENT DOCUMENTS**

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		5,795,976	08/18/1998	Oefner et al.
		5,833,986	11/10/1998	LaRochelle et al.

## **FOREIGN PATENT DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee

## **OTHER DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	
		Hirota et al., "Gain-of-Function Mutations of Platelet-Derived Growth Factor Receptor $\alpha$ Gene in Gastrointestinal Stromal Tumors," <i>Gastroenterology</i> 125:660-667 (2003).

**EXAMINER  
SIGNATURE:**

**DATE  
CONSIDERED:**

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.